Track Context Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Context Therapeutics Inc. Common Stock CNTX · Stock Open Context Therapeutics Inc. Common Stock in new tab

0.1808 USD
EPS
-0.46
P/B
0.64
ROE
-84.26
Beta
1.80
Target Price
4.14 USD
Loading chart...
Key Metrics
Earnings dateMarch 22, 2027
EPS-0.46
Book Value0.34
Price to Book0.64
Debt/Equity0.67
% Insiders1.571%
Estimates
Forward P/E-0.51
Forward EPS-0.42
Target Mean Price4.14

DCF valuation

Model fair value for Context Therapeutics Inc. Common Stock (CNTX)
Result
Sign in to run the valuation for CNTX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
7 analysts · consensus None · mean target 4.14 USD (low 2.00, high 5.00) · as of 12 Nov 2026
Low 2.00
Mean 4.14
High 5.00
Price 0.1808
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Context Therapeutics Inc. Common Stock Logo Context Therapeutics Inc. Common Stock Analysis (CNTX)

United States Health Care Official Website Stock

Is Context Therapeutics Inc. Common Stock a good investment? Context Therapeutics Inc. Common Stock (CNTX) is currently trading at 0.1808 USD. Market analysts have a consensus price target of 4.14 USD. This suggests a potential upside from current levels.

Earnings Schedule: Context Therapeutics Inc. Common Stock is expected to release its next earnings report on March 22, 2027. The market consensus estimate for Forward EPS is -0.42.

Investor FAQ

Does Context Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Context Therapeutics Inc. Common Stock?

Context Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 22, 2027. The company currently has a trailing EPS of -0.46.

Company Profile

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Exchange Ticker
NMS (United States) CNTX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion